MacroGenics, Inc. (MGNX) Stock Price Today & Analysis

Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
About MacroGenics, Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
FAQ
- Download the Gotrade app from the App Store or Google Play.
- Create an account and complete KYC.
- Make a deposit.
- Search for the code "MGNX", then tap "Trade".
- Tap the "Buy" button.
- Enter the amount you want to buy. You have two options:
- Buy MGNX by number of shares.
- Buy fractional shares in dollars, starting from $1.
- Swipe up to confirm your order—done!
- Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
- Review revenue and earnings growth.
- Check margins and cash flow.
- Evaluate business outlook and the company's position within its industry.





